Can you give us an example of a real world patient with a rare or refractory cancer whose treatment course was altered by an NGS-based FoundationOne Report?

Can you give us an example of a real world patient with a rare or refractory cancer whose treatment course was altered by an NGS-based FoundationOne Report?

Can you give us an example of a real world patient with a rare or refractory cancer whose treatment course was altered by an NGS-based FoundationOne Report?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Prof. Matthew Krebs, MD, PhD

Prof. Matthew Krebs, MD, PhD

Clinical Senior Lecturer
Experimental Cancer Medicine
Honorary Consultant
Medical Oncology
The University of Manchester
Greater Manchester, UK